MarketPulse

CASGEVY approval

2 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

CRISPR Therapeutics Eyes Major Year With Pipeline Catalysts Ahead

CRISPR Therapeutics faces pivotal 2024 with multiple clinical trial catalysts, including phase 2 and phase 1 data expected to drive stock movement amid elevated biotech volatility.
VRTXCRSPCRISPR gene editingCASGEVY approval
Investing.comInvesting.com··Chris Markoch

CRISPR Therapeutics Rallies on Pipeline Momentum Despite Quarterly Losses

CRISPR stock rallied 12% on pipeline momentum despite quarterly losses and minimal revenue, buoyed by cash reserves and CTX611 candidate progress.
VRTXCRSPrevenue recognitionbiotech pipeline